Merck & Co's Dificid (fidaxomicin) Receives FDA's Approval to Treat Clostridioides difficile in Children Aged Six Months and Older
Shots:
- The US FDA has approved NDA for Dificid oral suspension and sNDA for Dificid tablets for the treatment of Clostridioides difficile-associated diarrhea (CDAD) in patients aged ≥6mos.
- The approval is based on P-III SUNSHINE study assessing Dificid (bid) vs vancomycin (q4d) in 148 patients in a ratio (2:1) aged <18 yrs. with confirmed CDI resulted in CDAD clinical response in the overall pediatric population (77.6% vs 70.5%)- CR & no CDAD reoccurrence (68.4% vs 50.0%)
- Merck & Co’s (MSD outside the United States and Canada) Dificid is a macrolide antibacterial medicine indicated in adults and pediatric patients aged≥ 6mos. to treat CDAD and has received the US FDA’s PR status for both applications
Click here to read full press release/ article
Ref: Merck | Image: Merck
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com